South Korean molecular diagnostics firm Seegene announced after the close of the market on Tuesday that the US Food and Drug Administration has granted Emergency Use Authorization for the firm's Allplex 2019-nCoV Assay

A new study launched by scientists at Hannover Medical School (MHH) in Germany is determined to find out why patients respond differently to COVID-19.

Two months into the COVID-19 pandemic, the number of SARS-CoV-2 molecular diagnostic tests across the US remains woefully inadequate.

In the months since SARS-CoV-2 emerged and began spreading, researchers have been attempting to collect new data to understand the virus and COVID-19 disease it causes.

Genomic epidemiology papers from two independent teams are exploring potential sources of recent SARS-CoV-2 introductions to China's Guangdong province and to Connecticut, respectively

A new consortium spearheaded by the New York Genome Center aims to foster and organize genomic COVID-19 research in the New York metropolitan area.

A public-private consortium in Israel will collect samples and sequence genomes from thousands of COVID-19 patients in an effort to identify protective and risk-bearing genetic factors with the hopes of discovering new diagnostic and treatment methods.

This article has been updated from a previous version to include additional information about the saliva collection device specified in the EUA summary.

Lawmakers on Thursday called on the US Food and Drug Administration to provide information about the accuracy of the various SARS-CoV-2 diagnostics being used in response to the ongoing pandemic.

Prompted in part by the COVID-19 pandemic, the T.H. Chan School of Public Health at Harvard University

African genomics research company 54gene said on Tuesday that it has closed a $15 million Series A financing round.

A multi-omic analysis of high-grade serous ovarian cancer has uncovered molecular differences between clinical subgroups of the disease.

The US Food and Drug Administration on Monday granted Emergency Use Authorization to two lab-developed real-time RT-PCR tests for SARS-CoV-2, the virus that causes coronavirus disease COVID-19.

Illumina reported after the close of the market on Tuesday preliminary first quarter revenues of approximately $858 million. The firm also withdrew its full-year revenue guidance due to disruption from the COVID-19 pandemic.

Fluidigm said after the close of the market on Tuesday that it expects Q1 revenues of approximately $27.6 million.